SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

New Audio: Interview with NanoViricides CEO Eugene Seymour

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
DaysOnTheBeach Member Profile
 
Followed By 6
Posts 2,226
Boards Moderated 0
Alias Born 07/31/06
160x600 placeholder
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/14/2017 5:25:18 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) "Edgar (US Regulatory)" - 11/8/2017 5:18:02 PM
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November ... "PR Newswire (US)" - 11/6/2017 7:00:00 AM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 10/27/2017 6:08:02 AM
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Cente... "PR Newswire (US)" - 10/26/2017 7:00:00 AM
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of th... "PR Newswire (US)" - 10/17/2017 7:00:00 AM
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials "PR Newswire (US)" - 9/29/2017 7:30:00 AM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/28/2017 4:51:22 PM
NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference... "PR Newswire (US)" - 9/11/2017 9:04:00 AM
NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin "PR Newswire (US)" - 7/10/2017 7:00:00 AM
NanoViricides' Poster "Novel NanoviricidesĀ® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented... "PR Newswire (US)" - 6/26/2017 9:00:00 AM
NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology "PR Newswire (US)" - 6/20/2017 7:00:00 AM
NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York... "PR Newswire (US)" - 6/13/2017 7:00:00 AM
NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell ... "PR Newswire (US)" - 6/6/2017 5:30:00 PM
NanoViricides Files Quarterly Report for Period Ending 2017-03-31 "PR Newswire (US)" - 5/16/2017 7:50:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/15/2017 5:03:04 PM
NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Compan... "PR Newswire (US)" - 4/26/2017 5:00:00 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 4/26/2017 6:02:18 AM
Securities Registration Statement (simplified Form) (s-3/a) "Edgar (US Regulatory)" - 4/18/2017 4:57:18 PM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 3/1/2017 6:10:07 AM
NanoViricides Files Quarterly Report for Period Ending 2016-12-31 "PR Newswire (US)" - 2/16/2017 7:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/14/2017 6:02:28 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/13/2017 5:33:10 PM
NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New... "PR Newswire (US)" - 2/13/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 2/3/2017 1:27:25 PM
DaysOnTheBeach   Thursday, 11/15/07 11:03:25 PM
Re: None
Post # of 136198 
New Audio: Interview with NanoViricides CEO Eugene Seymour conducted by WallStreetReporter.com web site (first posted by Greatimes)

http://www.wallstreetreporter.com/page.php?page=featured&tab=2&id=27515

I've transcribed some highlights which seem to include never before disclosed information regarding future strategic partnerships involving both government and commercial entities, the relative monetary value of the existing partnerships to the company, and future marketing and revenue possibilities for NanoViricides drugs. All quotes are from Dr. Seymour, except where noted. Approximate times at which quotes occurred in the interview are listed:


"We are moving very quickly to file with the FDA with a number of our new drugs" [1:05]

"There are thousands of viruses [out there] . . . we are concentrating only on those that can be blockbusters" [2:23]

"Major area of concentration now is: HIV, Bird Flu, Human Flu, Rabies, Epidemic Keratoconjunctivitis, Dengue Fever, and Ebola" [2:28]

"I know it sounds like Science Fiction . . . but it seems to be working" [5:50]

"[The recent prodromal positive results confirming the effectiveness of our Rabies drug] is historic, and I don't think anybody understood the significance of this historic finding" [7:25]

"There's really nobody else doing exactly what we're doing in the antiviral space . . . using nanotechnology principles . . . we just haven't seen other people who are doing this, and if they are, we certainly haven't heard of them, and no one is as far along to my knowledge as we are" [7:40]

"Our first strategic partnerships are with governments and government agencies, with the Vietnamese government . . . are working with us on Rabies and Bird Flu. . . . Other partnerships that we have announced have been with U.S. government agencies . . . Walter Reed [working on Dengue Fever] and the more recently announced U.S. Army Medical Research for Infectious Diseases [working on Ebola]. [8:20]

"There are other agencies that are interested in working with us and those are currently in process" [9:15]

"They [our partnered agencies] do all the work, you see, and we figure that we have about $20 million to $30 million worth of in kind contributions by various government agencies saving us the aggravation of building a highly secure animal research laboratory . . . and this is to the advantage of our company and to the advantage of governments" [9:30]

"I am in discussions with other commercial companies about certain of our drugs but it's really too early to talk about that" 10:10

"There are a number of other bits of progress that have occurred that I have not made public yet, as you can imagine, doing agreements with the U.S. government great patience and lots of time . . . We are working with other government agencies trying to get these contracts completed so we can begin to announce them also" [12:35]

"In terms of our executive board, I'm beginning to build that now because I have a longer term goal of moving to the NASDAQ which will require a much expanded board, so I'm now in the process of building that board, to really give us the sort of help in the area of business that we're going to need when we deal with the large pharmaceutical companies" {13:40]

Interviewer: "Do you feel the investment community understands the direction of this company given the current stock price?" Seymour: "Absolutely not" [14:15]

"[our initial FDA filing] we would very much like to accomplish on probably Human Flu and Bird Flu drugs sometime next year [2008]. [14:40]

"In two to three years I hope to have a number of drugs into the FDA, and since these are for infectious diseases, some of which are lethal diseases, and of course it's all predicated on whether we get Fast Track Approval, whether we can invoke the Two Animal Rule and avoid human trials for effectiveness and only do a Phase I study for safety, if [the FDA] will allow that, then we can move through the process and be approved much more quickly . . . . there's been nothing like our drug system that's come to the FDA in the past, so we don't know how they are going to respond, but fortunately there's a tremendous need for all the drugs we have, and our initial indications are they will receive our applications quite favorably" [16:40]

"If things continue to work the way they've been working, then we have the potential for a significant number of drugs on the market . . . at least the first five of which . . . could have sales in excess of $1 billion dollars [each]. Now what we will do, of course, is have alliances with large pharmaceutical companies and work on milestone payments and up-front payments as well as royalty payments, rather than having to build an entire marketing effort" [18:05]


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist